Mephedrone
Mephedrone is a synthetic entactogen-stimulant of the substituted cathinone class. Originally synthesized in 1929, it was rediscovered in 2003 and rapidly gained popularity as an online research chemical between 2007 and 2009, particularly in the United Kingdom. Its effects are frequently compared to a combination of MDMA and cocaine. Mephedrone's short duration and intense rush are associated with compulsive redosing, and it is sometimes misrepresented as MDMA.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of mephedrone can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of mephedrone can be broken down into several components which progressively intensify proportional to dosage. The general head space of mephedrone is described by many as one of extreme mental stimulation and powerful euphoria. It contains a large number of typical stimulant cognitive effects.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Mephedrone acts primarily as a substrate-type releasing agent and reuptake inhibitor at the serotonin, dopamine, and norepinephrine transporters. It preferentially releases serotonin over dopamine, functioning as a full releaser of serotonin but only a partial releaser of dopamine. Beyond its transporter-mediated effects, mephedrone is a potent near-full agonist at the serotonin 5-HT2A receptor and shows significant affinity for the 5-HT2B, 5-HT2C, and α2-adrenergic receptors, though it is inactive as an agonist at 5-HT2B. It also activates rodent TAAR1 at micromolar potencies but does not appear to act as an agonist at the human TAAR1.
Pharmacokinetics
Mephedrone is rapidly absorbed following oral or intranasal administration, with peak plasma concentrations typically reached within 0.5 to 1 hour. It readily crosses the blood-brain barrier (brain-to-plasma ratio of approximately 1.85 in rats) and has a plasma elimination half-life of approximately 2 hours. The drug undergoes extensive first-pass metabolism primarily via CYP2D6, with major phase I pathways including N-demethylation, ketone reduction, and tolyl group oxidation. Absolute bioavailability in rats is approximately 10%, consistent with substantial hepatic first-pass metabolism, and plasma protein binding is approximately 22%. Mephedrone exhibits enantioselective pharmacokinetics in which the R-(+) enantiomer reaches higher peak concentrations and persists longer than the S-(-) enantiomer.
Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
HighChronic use is considered highly addictive with an extreme potential for abuse and psychological dependence. The urge to redose is notoriously strong, particularly with insufflation, with many users reporting difficulty controlling their intake within a single session. Compulsive redosing patterns similar to or exceeding those of other euphoric stimulants are commonly described, leading to consumption of far more than intended.
Physical
LowPhysical dependence is unlikely to develop significantly. Withdrawal symptoms are minimal and not life-threatening, though dependence may manifest as restlessness, tremors, insomnia, and hyperactivity following cessation of regular use.
Toxicity
Acute cardiovascular effects including elevated blood pressure, increased heart rate, and vasoconstriction occur during intoxication; severe vasoconstriction resulting in bluish discolouration of extremities has been reported with repeated dosing over extended sessions at cumulative doses exceeding 600 mg.
Animal studies indicate mephedrone is a monoaminergic neurotoxin inducing serotonergic neurotoxicity; persistent serotonergic deficits have been observed following binge-like use patterns, particularly in warm environments, though some evidence suggests mephedrone may be less neurotoxic than corresponding amphetamines like MDMA at moderate doses.
Insufflation causes local irritation including pain, swelling, nosebleeds, and sinusitis; these effects are route-specific and occur primarily with heavy or repeated intranasal use.
One case of acquired methaemoglobinaemia with bluish discolouration of lips and fingers has been reported following insufflation of one gram; this appears to be a rare adverse effect.
Psychosis Risk
High doses may lead to psychotic reactions including hallucinations, delusions, and erratic behaviour. Anxiety and paranoia are more commonly reported adverse effects. The most severe psychiatric effects appear to be associated with high doses or prolonged use, and risk may be elevated in individuals with predisposition to schizophrenia.
Seizure Risk
Seizures have been documented in clinical case series, with one hospital report finding 20% of treated patients experienced seizures. A fatal case in Sweden involved convulsions. Individuals with pre-existing seizure disorders may be at elevated risk when using stimulants.
History & Culture
Discovery and Synthesis
Mephedrone was first synthesized in 1929 by Saem de Burnaga Sanchez, who published his work in the Bulletin de la Société Chimique de France under the chemical name "toluyl-alpha-monomethylaminoethylcetone." Following this initial synthesis, the compound remained an obscure product of academic
Legality
International
Mephedrone is not scheduled under the 1961, 1971, or 1988 UN drug-control conventions.
By Country
References
Source Pages
Citations
- (n.d.). Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au. https://www.legislation.gov.au/F2026L00633/latest/text1
- (n.d.). Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. tga.gov.au. https://www.tga.gov.au/products/regulations-all-products/legislation-and-legislative-instruments/poisons-standard-susmp1
- (n.d.). Suchtgiftverordnung, Anhang V.2. ris.bka.gv.at. https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=5&Artikel=&Gesetzesnummer=10011053&Paragraf=&Uebergangsrecht=1
- (n.d.). Suchtgiftverordnung, Anhang V.2. ris.bka.gv.at. https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=100110561
- (n.d.). Arrêté royal du 6 septembre 2017 réglementant les stupéfiants et les substances psychotropes, arts. 1 and 6. ejustice.just.fgov.be. https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- (n.d.). Arrêté royal du 6 septembre 2017 réglementant les stupéfiants et les substances psychotropes, arts. 1 and 6. ejustice.just.fgov.be. https://www.ejustice.just.fgov.be/cgi/article_body.pl?language=fr&pub_date=2017-09-26&numac=2017031231&caller=list1
- (n.d.). RDC nº 36, de 3 de agosto de 2011, updating Portaria SVS/MS nº 344/1998. gov.br. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- (n.d.). Popis droga, psihotropnih tvari i biljaka iz kojih se može dobiti droga te tvari koje se mogu uporabiti za izradu droga, NN 19/2023, as amended by NN 154/2024. narodne-novine.nn.hr. https://narodne-novine.nn.hr/clanci/sluzbeni/full/2023_02_19_331.html1
- (n.d.). Popis droga, psihotropnih tvari i biljaka iz kojih se može dobiti droga te tvari koje se mogu uporabiti za izradu droga, NN 19/2023, as amended by NN 154/2024. narodne-novine.nn.hr. https://narodne-novine.nn.hr/clanci/sluzbeni/2024_12_154_2555.html1
- (n.d.). Government Regulation No. 463/2013 Coll., on lists of addictive substances, Appendix No. 4 (List No. 4 of psychotropic substances), read with Act No. 167/1998 Coll. §§ 3(2) and 4. e-sbirka.gov.cz. https://e-sbirka.gov.cz/sb/2013/4631
- (n.d.). Government Regulation No. 463/2013 Coll., on lists of addictive substances, Appendix No. 4 (List No. 4 of psychotropic substances), read with Act No. 167/1998 Coll. §§ 3(2) and 4. e-sbirka.gov.cz. https://e-sbirka.gov.cz/sb/1998/1671
- (n.d.). Bekendtgørelse om euforiserende stoffer. retsinformation.dk. https://www.retsinformation.dk/eli/lta/2026/4051
- (n.d.). Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008), liite I; Huumausainelaki (373/2008), 5 §. finlex.fi. https://www.finlex.fi/fi/lainsaadanto/2008/5431
- (n.d.). Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008), liite I; Huumausainelaki (373/2008), 5 §. finlex.fi. https://www.finlex.fi/fi/lainsaadanto/2008/3731
- (n.d.). Arrêté du 7 juin 2010 modifiant l’arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. legifrance.gouv.fr. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT0000223314481
- (n.d.). Arrêté du 7 juin 2010 modifiant l’arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. legifrance.gouv.fr. https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2026-06-121
- (n.d.). Betäubungsmittelgesetz, Anlage I. gesetze-im-internet.de. https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html1
- (n.d.). 78/2022. (XII. 28.) BM rendelet az ellenőrzött anyagokról. njt.hu. https://njt.hu/jogszabaly/2022-78-20-0A.21
- (n.d.). Narcotic Drugs and Psychotropic Substances Act, 1985, Schedule. indiacode.nic.in. https://www.indiacode.nic.in/bitstream/123456789/6834/1/narcotic-drugs-and-psychotropic-substances-act-1985.pdf1
- (n.d.). Minister of Health Regulation No. 15 of 2025 (Permenkes No. 15 Tahun 2025) on Changes to Narcotics Classification, Appendix A, List of Group I Narcotics, item 75. jdih.kemkes.go.id. https://jdih.kemkes.go.id/documents/peraturan-menteri-kesehatan-nomor-15-tahun-20251
- (n.d.). Minister of Health Regulation No. 15 of 2025 (Permenkes No. 15 Tahun 2025) on Changes to Narcotics Classification, Appendix A, List of Group I Narcotics, item 75. jdih.kemkes.go.id. https://jdih.kemkes.go.id/storage/documents/pdfs/2025permenkes015.pdf1
- (n.d.). Misuse of Drugs Regulations 2017, S.I. No. 173/2017, Schedule 1. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2017/si/173/made/en/print1
- (n.d.). Decreto 16 giugno 2010. gazzettaufficiale.it. https://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.codiceRedazionale=10A07887&atto.dataPubblicazioneGazzetta=2010-06-25&atto.tipoProvvedimento=DECRETO1
- (n.d.). Cabinet Order Designating Narcotics, Narcotic Raw Materials Plants, Psychotropics and Narcotic/Psychotropic Raw Materials, item 129, under the Narcotics and Psychotropics Control Act. laws.e-gov.go.jp. https://laws.e-gov.go.jp/law/402CO0000000238/1
- (n.d.). Cabinet Order Designating Narcotics, Narcotic Raw Materials Plants, Psychotropics and Narcotic/Psychotropic Raw Materials, item 129, under the Narcotics and Psychotropics Control Act. laws.e-gov.go.jp. https://laws.e-gov.go.jp/law/328AC0000000014/1
- (n.d.). Ley General de Salud, artículo 245. dof.gob.mx. https://dof.gob.mx/nota_detalle_popup.php?codigo=56088301
- (n.d.). Opiumwet, lijst I. wetten.overheid.nl. https://wetten.overheid.nl/BWBR0001941/2026-01-011
- (n.d.). Opiumwet, lijst I. zoek.officielebekendmakingen.nl. https://zoek.officielebekendmakingen.nl/stb-2012-201.html1
- (n.d.). Forskrift om narkotika, FOR-2013-02-14-199. lovdata.no. https://lovdata.no/forskrift/2013-02-14-199/%C2%A741
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, consolidated text Dz.U. 2024 poz. 1139. eli.gov.pl. https://eli.gov.pl/eli/DU/2024/1139/ogl1
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, consolidated text Dz.U. 2024 poz. 1139. eli.gov.pl. https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, consolidated text Dz.U. 2024 poz. 1139. eli.gov.pl. https://eli.gov.pl/api/acts/DU/2024/536/text.html1
- (n.d.). Decreto-Lei n.º 15/93, de 22 de janeiro, Tabela II-A, as amended by Lei n.º 13/2012, de 26 de março. diariodarepublica.pt. https://diariodarepublica.pt/dr/legislacao-consolidada/decreto-lei/1993-345500751
- (n.d.). Decreto-Lei n.º 15/93, de 22 de janeiro, Tabela II-A, as amended by Lei n.º 13/2012, de 26 de março. diariodarepublica.pt. https://diariodarepublica.pt/dr/detalhe/lei/13-2012-5539321
- (n.d.). Decreto-Lei n.º 15/93, de 22 de janeiro, Tabela II-A, as amended by Lei n.º 13/2012, de 26 de março. files.dre.pt. https://files.dre.pt/gratuitos/1s/2012/03/06100.pdf1
- (n.d.). Government Resolution No. 681 of 30 June 1998, List I. publication.pravo.gov.ru. https://publication.pravo.gov.ru/Document/View/00012022052700201
- (n.d.). Misuse of Drugs Act 1973, First Schedule, Part 1. sso.agc.gov.sg. https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- (n.d.). Act No. 139/1998 Z.z. on narcotic drugs, psychotropic substances and preparations. slov-lex.sk. https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/1998/139/202601011
- (n.d.). Enforcement Decree of the Narcotics Control Act, Attached Table 3, item 22. law.go.kr. https://www.law.go.kr/%EB%B2%95%EB%A0%B9/%EB%A7%88%EC%95%BD%EB%A5%98%EA%B4%80%EB%A6%AC%EC%97%90%EA%B4%80%ED%95%9C%EB%B2%95%EB%A5%A0%EC%8B%9C%ED%96%89%EB%A0%B91
- (n.d.). Enforcement Decree of the Narcotics Control Act, Attached Table 3, item 22. law.go.kr. https://www.law.go.kr/LSW/flDownload.do?bylClsCd=110201&flSeq=1488406891
- (n.d.). Orden SPI/201/2011, de 3 de febrero. boe.es. https://www.boe.es/diario_boe/txt.php?id=BOE-A-2011-24901
- (n.d.). Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. lakemedelsverket.se. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf1
- (n.d.). Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. riksdagen.se. https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- (n.d.). Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI). fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- (n.d.). Notification of the Ministry of Public Health Re: Specifying Category 1 Narcotics, B.E. 2565 (2022). ratchakitcha.soc.go.th. https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/253/T_0008.PDF1
- (n.d.). Notification of the Ministry of Public Health Re: Specifying Category 1 Narcotics, B.E. 2565 (2022). permitfortraveler.fda.moph.go.th. https://permitfortraveler.fda.moph.go.th/nct_permit_main/Upload/NARCO_list_update_15_09_2025_NEW.pdf1
- (n.d.). Council of Ministers Decision No. 2012/2861 on Subjecting Certain Substances to Law No. 2313 on the Control of Narcotic Drugs. narkotik.pol.tr. https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/Arsiv/TUBIM/Documents/TURKIYE%20UYUSTURUCU%20RAPORU%202012.pdf1
- (n.d.). Council of Ministers Decision No. 2012/2861 on Subjecting Certain Substances to Law No. 2313 on the Control of Narcotic Drugs. resmigazete.gov.tr. https://www.resmigazete.gov.tr/eskiler/2012/03/20120322.htm1
- (n.d.). Council of Ministers Decision No. 2012/2861 on Subjecting Certain Substances to Law No. 2313 on the Control of Narcotic Drugs. adlisicil.adalet.gov.tr. https://adlisicil.adalet.gov.tr/Resimler/SayfaDokuman/19820191510085237%20Say%C4%B1l%C4%B1%20T%C3%BCrk%20Ceza%20Kanunu.pdf1
- (n.d.). Cabinet of Ministers Resolution No. 770, Table I, List No. 2. zakon.rada.gov.ua. https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF#n171
- (n.d.). Cabinet of Ministers Resolution No. 770, Table I, List No. 2. zakon.rada.gov.ua. https://zakon.rada.gov.ua/laws/show/373-2010-%D0%BF1
- (n.d.). Federal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, Schedule 5. uaelegislation.gov.ae. https://uaelegislation.gov.ae/en/legislations/1540/regulations/501/download1
- (n.d.). Federal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, Schedule 5. uaelegislation.gov.ae. https://uaelegislation.gov.ae/en/legislations/15401
- (n.d.). Misuse of Drugs Act 1971 (Amendment) Order 2010, S.I. 2010/1207. legislation.gov.uk. https://www.legislation.gov.uk/uksi/2010/1207/pdfs/uksi_20101207_en.pdf1
- (n.d.). Controlled Substances Act, 21 U.S.C. § 812(c). uscode.house.gov. https://uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title21-section8121
- (n.d.). Controlled Substances Act, 21 U.S.C. § 812(c). ecfr.gov. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.111
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Mephedrone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.